Evidence map›Paper›PMID 40394764›Full record

ArticleChinese medical journal2026

Proteomic analysis reveals modulation of key proteins in follicular thyroid cancer progression.

Xue Cai, Rui Sun, Liang Yang, Nan Yao, Yaoting Sun, Guangmei Zhang, Weigang Ge, Yan Zhou, Zhiqiang Gui, Yu Wang and 40 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors.

Xue CaiCollege of Life Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.
Rui SunAffiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, Westlake University, Hangzhou, Zhejiang 310024, China.
Liang YangWestlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang 310030, China.
Nan YaoAffiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, Westlake University, Hangzhou, Zhejiang 310024, China.
Yaoting SunAffiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, Westlake University, Hangzhou, Zhejiang 310024, China.
Guangmei ZhangAffiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, Westlake University, Hangzhou, Zhejiang 310024, China.
Weigang GeWestlake Omics (Hangzhou) Biotechnology Co., Ltd., Hangzhou, Zhejiang 310024, China.
Yan ZhouAffiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, Westlake University, Hangzhou, Zhejiang 310024, China.
Zhiqiang GuiDepartment of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China.
Yu WangDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Haitao ZhengDepartment of Thyroid Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, China.
Dong XuZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
Yongfu ZhaoDepartment of General Surgery, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116027, China.
Xiu NieDepartment of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Zhiyan LiuDepartment of Pathology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200235, China.
Hao ZhangDepartment of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China.
Pingping HuAffiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, Westlake University, Hangzhou, Zhejiang 310024, China.
Honghan ChengAffiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, Westlake University, Hangzhou, Zhejiang 310024, China.
Zhangzhi XueAffiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, Westlake University, Hangzhou, Zhejiang 310024, China.
Jiatong WangAffiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, Westlake University, Hangzhou, Zhejiang 310024, China.
Jing YuAffiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, Westlake University, Hangzhou, Zhejiang 310024, China.
Chuang ChenDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
Dingcun LuoDepartment of Surgical Oncology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang 310006, China.
Jingqiang ZhuDivision of Thyroid Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Tong LiuDepartment of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, China.
Yifeng ZhangDepartment of Medical Ultrasound, Shanghai Tenth People's Hospital; Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, Shanghai 200072, China.
Qijun WuDepartment of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China.
Qiaonan GuoDepartment of Pathology, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing 400037, China.
Wanyuan ChenDepartment of Pathology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310006, China.
Jianbiao WangDepartment of Head and Neck Surgery, Institute of Micro-Invasive Surgery of Zhejiang University, The Affiliated Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, China.
Wenjun WeiDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xiangfeng LinDepartment of Thyroid Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, China.
Jincao YaoZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
Guangzhi WangDepartment of General Surgery, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116027, China.
Li PengDepartment of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Shuyi LiuDepartment of Pathology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200235, China.
Zhihong WangDepartment of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China.
Hanqing LiuDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
Jiaxi WangDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
Fan WuDepartment of Surgical Oncology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang 310006, China.
Zhennan YuanDepartment of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, China.
Tingting GongDepartment of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China.
Yangfan LyuDepartment of Pathology, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing 400037, China.
Jingjing XiangDepartment of Pathology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang 310006, China.
Yi ZhuAffiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, Westlake University, Hangzhou, Zhejiang 310024, China.
Lei XieDepartment of Head and Neck Surgery, Institute of Micro-Invasive Surgery of Zhejiang University, The Affiliated Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, China.
Minghua GeOtolaryngology and Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310006, China.
Haixia GuanDepartment of Endocrinology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, China.
Tiannan GuoCollege of Life Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.
We-TEC Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCytopathology cannot be used to reliably distinguish follicular thyroid adenoma (FTA) from follicular thyroid carcinoma (FTC), the second most common form of thyroid cancer, because they exhibit nearly identical cellular morphology. Given the challenges in diagnosis and treatment, this study aims to identify the mechanisms underlying FTC.

methodsUsing parallel reaction monitoring-mass spectrometry (PRM-MS) assays, we identified and quantified 94 differentially expressed protein candidates from a retrospective cohort of 1085 FTC and FTA tissue samples from 18 clinical centers. Of these targeted proteins, those with the potential for distinguishing FTC from FTA were prioritized using machine learning. Co-immunoprecipitation (co-IP) and immunofluorescence co-localization assays, as well as gene interference, overexpression, and immunohistochemistry (IHC) experiments, were used to investigate the interactions and cellular functions of selected proteins.

resultsUsing machine learning models and feature selection methods, 30 of the 94 candidates were prioritized as key proteins. Co-IP and immunofluorescence co-localization assays using FTC cell lines revealed interactions among insulin-like growth factor 2 receptor (IGF2R), major vault protein (MVP), histone deacetylase 1 (HDAC1), and histone H1.5 (H1-5). Gene interference and overexpression experiments in FTC-133 cells confirmed the promotional role of these proteins in cell proliferation. IHC assays of patient samples further confirmed elevated expression of these four proteins in FTC compared with that in FTA.

conclusionsOur findings underscore the utility of advanced proteomic techniques in elucidating the molecular underpinnings of FTC, highlighting the potential significance of IGF2R, MVP, HDAC1, and H1-5 in FTC progression, and providing a foundation for the exploration of targeted therapies.

Indexed as

Adenocarcinoma, FollicularProteomicsThyroid NeoplasmsCell Line, TumorHistone Deacetylase 1HistonesHumansImmunohistochemistryMajor Vault ProteinHistone Deacetylase 1HistonesMajor Vault ProteinHistone deacetylase 1Histone H1.5Insulin-like growth factor 2 receptorMachine learningMajor vault proteinParallel reaction monitoring mass spectrometryProteomicsThyroid cancer

Identifiers

PMID40394764
PMCPMC13384632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.